市场调查报告书
商品编码
1004267

自动注射器的全球市场

The global auto injector market by product type, therapy type, indication, route of distribution, end user & regions

出版日期: | 出版商: SPER Market Research Pvt. Ltd. | 英文 216 Pages | 商品交期: 最快1-2个工作天内

价格
  • 全貌
  • 简介
  • 目录
简介

全球自动注射器市场,预计从2019年到2027年以18.2%的年复合成长率发展,从2019年的401亿美元到2027年达1,531亿美元。该市场的主要成长要素,是标靶治疗的普及,过敏性反应的发生率上升,对药物的自我给药偏好高涨,使用方便的好处,法规当局的批准数量增加,自动注射器的非专利版的利用可能性,有利的偿付和政府的辅助,技术的进步等。还有生物制药的专利到期也成为市场成长机会。

本报告提供全球自动注射器市场的相关调查,市场成长及阻碍因素,机会和课题,各治疗、类型、给药途径、终端用户、地区的市场分析,竞争情形,主要企业的简介等资讯。

目录

第1章 简介

第2章 调查手法

第3章 摘要整理

第4章 重要考察

第5章 市场概要

  • 简介
  • 市场动态
    • 成长要素
    • 阻碍因素
    • 机会
    • 课题
  • 自动注射器市场COVID-19的影响

第6章 产业考察

  • 简介
  • 产业趋势

第7章 自动注射器市场:各治疗(2020-2027)

  • 类风湿性关节炎
  • 糖尿病
  • 多发性硬化症
  • 过敏性反应
  • 其他

第8章 自动注射器市场:各类型(2020-2027)

  • 抛弃式自动注射器
  • 可重覆使用自动注射器

第9章 自动注射器市场:各给药途径(2020-2027)

  • 皮下
  • 肌肉内

第10章 自动注射器市场:各终端用户(2020-2027)

  • 居家照护
  • 医院及诊疗所
  • 门诊病人

第11章 自动注射器市场:各地区(2020-2027)

  • 北美
    • 美国
    • 加拿大
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 义大利
    • 西班牙
    • 其他欧洲
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 其他亚太地区
  • 南美
  • 中东和非洲

第12章 竞争情形

  • 简介
  • 竞争现况与趋势
    • 产品销售
    • 联盟,合作,契约
    • 收购
    • 扩张
    • 其他开发

第13章 企业简介

  • Abbvie Inc.
  • Amgen
  • Elli Lilly and Company
  • Mylan
  • Ypsomed
  • Becton, Dickinson, and Company
  • Glaxosmithkline Plc.
  • Johnson & Johnson
  • Teva Pharmaceutical Industries
  • Antares Pharma, Inc.
  • Merck KGAA
  • Meridian Medical Technologies, Inc.
  • Roche
  • Bespak
  • Bayer AG
  • Bristol-Myers Squibb Company
  • SHL Medical
  • Haselmeter
  • Owen Mumford
  • Ravimed

第14章 附录

  • 1)讨论指南
  • 2)可利用的客制化
  • 3)相关报告
目录

The global autoinjectors market is projected to reach USD 153.1 billion by 2027 from USD 40.1 billion in 2019, at a CAGR of 18.2% from 2019 to 2027. Market growth is largely driven by the growing prevalence of targeted therapies, the rising incidence of anaphylaxis, rising preference for self-administration of drugs, usability advantages, the increasing number of regulatory approvals, the availability of generic versions of autoinjectors, favourable reimbursements and government support, and technological advancements. The patent expiry of biologics is also expected to provide growth opportunities for players in the market.

On the other hand, the preference for alternative routes of drug delivery such as oral diabetic agents and nasal epinephrine sprays is expected to limit the adoption of autoinjector devices. Some of the key players operating in the autoinjectors market include AbbVie Inc. (US), Mylan (US), Eli Lilly and Company (US), Ypsomed (Switzerland), Amgen (US), Becton, Dickinson and Company (US), GlaxoSmithKline plc (UK), Johnson & Johnson (US), Teva Pharmaceutical (Israel), Antares Pharma (US), Merck KGaA (Germany).

The COVID-19 pandemic has resulted in a global healthcare crisis, causing a shift in healthcare delivery in most regions. Moreover, the slowdown in clinical trial recruitment has delayed the introduction of new therapies. These factors could have had a negative impact on the autoinjectors market, especially with their use in healthcare institutions in early 2020. However, the pandemic's overall effect on the autoinjectors is considered positive, especially in the forecast period, due to several factors. Firstly, the demand for effective home care and remote monitoring has increased the relevance of autoinjectors for patients to conveniently and easily manage chronic illnesses and allergies without visiting the hospital. This has been especially true in the case of diabetes, Crohn's disease, a rheumatoid arthritis patient relying on prefilled syringes and autoinjectors to manage their condition at home.

The autoinjectors market, by therapy, is segmented into rheumatoid arthritis, multiple sclerosis, anaphylaxis, diabetes, multiple sclerosis, and other therapies (includes cardiovascular diseases, migraine treatment, anaemia, and progesterone therapy). In 2019, rheumatoid arthritis accounted for the largest share of autoinjectors market. The large share of this segment is mainly attributed to its high prevalence. The increasing incidence of RA fuels the demand for autoinjectors for this therapy segment. According to the CDC, an estimated 43.7 million adults (22.7% of the total population) in the US are affected annually by some form of arthritis, RA, gout, lupus, or fibromyalgia.

Based on type, the autoinjectors market is segmented into reusable and disposable autoinjectors. In 2018, the disposable autoinjectors segment accounted for the largest share of the global autoinjectors market. Disposable autoinjectors are the most-preferred autoinjectors due to their ease of use and the presence of a built-in glass syringe (eliminates the need of manually loading the glass syringe), which makes it more convenient for patients with reduced dexterity or visual impairments.

Based on route of administration, the autoinjectors market is segmented intramuscular and subcutaneous. Patients use autoinjectors for intramuscular and subcutaneous administration of various drugs for the treatment of diseases such as rheumatoid arthritis, multiple sclerosis, anaphylaxis, diabetes, migraine, anaemia, and cancer. The subcutaneous segment accounted for the largest share and it is expected to witness fastest growth during the forecast period. The large share of this segment can primarily be attributed to the growing number of product approvals by regulatory bodies for the treatment of chronic diseases.

Based on end users, the autoinjectors market is segmented into home care settings, hospitals & clinics, and ambulatory care settings. The home care settings segment accounted for the largest share of the autoinjectors market in 2018. The large share of this end-user segment can primarily be attributed to the rapid growth in the geriatric population across the globe and the growing need for cost-effective drug administration.

Geographically, the autoinjectors market is segmented into North America, Europe, the Asia Pacific, Latin America, and Middle East & Africa. Growth in the Asia Pacific market is majorly driven by the large diabetes population and increasing healthcare expenditure which has drawn a number of major autoinjector device manufacturers to this region. These companies are increasing their presence in the Asia Pacific market through several approaches, such as establishing sales offices and partnering with local pharmaceutical companies.

Table of Contents

1. Introduction

2. Research Methodology

3. Executive Summary

4. Premium Insights

5. Market Overview

  • 1) Introduction
  • 2) Market Dynamics
    • i. Drivers
    • ii. Restraints
    • iii. Opportunities
    • iv. Challenges
  • 3) COVID-19 Impact of the Autoinjectors Market

6. Industry Insights

  • 1) Introduction
  • 2) Industry Trends

7. Autoinjectors Market, By Therapy, 2020-2027 (USD Million)

  • 1) Rheumatoid Arthritis
  • 2) Diabetes
  • 3) Multiple Sclerosis
  • 4) Anaphylaxis
  • 5) Other Therapies

8. Autoinjectors Market, By Type, 2020-2027 (USD Million)

  • 1) Disposable Autoinjectors
  • 2) Reusable Autoinjectors

9. Autoinjectors Market, By Route of Administration, 2020-2027 (USD Million)

  • 1) Subcutaneous
  • 2) Intramuscular

10. Autoinjectors Market, By End User, 2020-2027 (USD Million)

  • 1) Home Care
  • 2) Hospitals & Clinics
  • 3) Ambulatory Care Settings

11. Autoinjectors Market, By Geography, 2020-2027 (USD Million)

  • 1) North America
    • i. US
    • ii. Canada
  • 2) Europe
    • i. Germany
    • ii. UK
    • iii. France
    • iv. Italy
    • v. Spain
    • vi. Rest of Europe
  • 3) Asia-Pacific
    • i. China
    • ii. Japan
    • iii. India
    • iv. Rest of Asia-Pacific
  • 4) Latin America
  • 5) Middle East and Africa

12. Competitive Landscape

  • 1) Introduction
  • 2) Competitive Situation and Trends
    • i. Product Launches
    • ii. Partnerships, Collaborations, and Agreements
    • iii. Acquisitions
    • iv. Expansions
    • v. Other Developments

13. Company Profiles

  • 1) Abbvie Inc.
  • 2) Amgen
  • 3) Elli Lilly and Company
  • 4) Mylan
  • 5) Ypsomed
  • 6) Becton, Dickinson, and Company
  • 7) Glaxosmithkline Plc.
  • 8) Johnson & Johnson
  • 9) Teva Pharmaceutical Industries
  • 10) Antares Pharma, Inc.
  • 11) Merck KGAA
  • 12) Meridian Medical Technologies, Inc.
  • 13) Roche
  • 14) Bespak
  • 15) Bayer AG
  • 16) Bristol-Myers Squibb Company
  • 17) SHL Medical
  • 18) Haselmeter
  • 19) Owen Mumford
  • 20) Ravimed

14. Appendix

  • 1) Discussion Guide
  • 2) Available Customizations
  • 3) Related Reports